Health Care Select Sector SPDR® ETF (XLV)
78.36
+0.36 +0.46%
NYSE Arca
Aug 21, 16:58
Delayed 2m
USD
XLV Key Stats
| Expense Ratio | 0.14% |
| Share Class Assets Under Management | 17.43B |
| 30-Day Average Daily Volume | Upgrade |
| Net Asset Value | 78.01 |
| Discount or Premium to NAV | -0.01% |
| Turnover Ratio | 8.00 |
View All XLV News
XLV News
-
WireHeadlineTime (ET)
-
MT Newswires08/21 13:31
-
Yahoo08/21 10:50
-
MT Newswires08/21 09:28
-
Yahoo08/21 09:06
-
MT Newswires08/18 13:26
-
Yahoo08/18 11:59
-
Yahoo08/18 10:20
-
MT Newswires08/18 09:21
-
Yahoo08/18 09:19
-
MT Newswires08/17 13:24
XLV Performance
| Total Return | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|
| 1M | -2.38% | -3.58% | 8 |
| 3M | 4.66% | 2.80% | 15 |
| 6M | 6.70% | 5.18% | 28 |
| 1Y | 6.48% | 7.50% | 59 |
| 3Y | 9.32% | 7.29% | 28 |
| 5Y | 17.02% | 16.59% | 51 |
| 10Y | 10.68% | 11.41% | 59 |
XLV Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.00 | 0.00 | 0.00 |
| Stock | 99.92% | 99.92% | 0.00 |
| Bond | 0.00 | 0.00 | 0.00 |
| Convertible | 0.00 | 0.00 | 0.00 |
| Preferred | 0.00 | 0.00 | 0.00 |
| Other | 0.08% | 0.08% | 0.00 |
XLV Region Exposure
| Americas | 100.0% |
| North America | 100.0% |
| Latin America | 0.00 |
| Greater Europe | 0.00 |
| United Kingdom | 0.00 |
| Europe Developed | 0.00 |
| Europe Emerging | 0.00 |
| Africa/Middle East | 0.00 |
| Greater Asia | 0.00 |
| Japan | 0.00 |
| Australasia | 0.00 |
| Asia Developed | 0.00 |
| Asia Emerging | 0.00 |
| Market Classification | |
| % Developed Markets | 100.0% |
| % Emerging Markets | 0.00 |
XLV Stock Sector Exposure
| Basic Materials | 0.00 |
| Communication Services | 0.00 |
| Consumer Cyclical | 0.00 |
| Consumer Defensive | 0.00 |
| Energy | 0.00 |
| Financial Services | 0.00 |
| Healthcare | 99.37% |
| Industrials | 0.00 |
| Real Estate | 0.00 |
| Technology | 0.63% |
| Utilities | 0.00 |
XLV Stock Market Capitalization
| Giant | 48.68% |
| Large | 42.51% |
| Medium | 8.70% |
| Small | 0.10% |
| Micro | 0.00 |
XLV Stock Style Exposure
| Large Cap Value | 30.68% |
| Large Cap Blend | 26.08% |
| Large Cap Growth | 34.44% |
| Mid Cap Value | 1.47% |
| Mid Cap Blend | 3.25% |
| Mid Cap Growth | 3.99% |
| Small Cap Value | 0.00 |
| Small Cap Blend | 0.10% |
| Small Cap Growth | 0.00 |
View More Holdings
As of Aug. 18, 2017
XLV Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 12.00% | 133.43 | +0.60% |
| PFE | Pfizer Inc | 6.55% | 32.76 | +0.26% |
| UNH | UnitedHealth Group Inc | 6.22% | 191.44 | +0.32% |
| MRK | Merck & Co Inc | 5.65% | 61.98 | +0.80% |
| AMGN | Amgen Inc | 4.13% | 168.24 | +0.57% |
| MDT | Medtronic PLC | 3.85% | 83.49 | +0.10% |
| ABBV | AbbVie Inc | 3.74% | 70.68 | +1.03% |
| CELG | Celgene Corp | 3.34% | 127.39 | -0.20% |
| GILD | Gilead Sciences Inc | 3.16% | 72.61 | +0.69% |
| BMY | Bristol-Myers Squibb Company | 3.14% | 56.64 | +0.39% |
Advertisement
XLV One Page Reports
- One Page Report Download
XLV Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | SPDR State Street Global Advisors |
| Benchmark Index | |
|---|---|
S&P Health Care Select Sector TR USD |
100.0% |
XLV Manager Info
| Name | Tenure |
|---|---|
| Dwayne Hancock | 0.49 yrs |
| Karl Schneider | 2.42 yrs |
| Michael Feehily | 6.42 yrs |
XLV Net Fund Flows
| 1M | 210.32M |
| 3M | 884.43M |
| 6M | 1.985B |
| YTD | 2.097B |
| 1Y | 3.519B |
| 3Y | 5.212B |
| 5Y | 6.487B |
| 10Y | 8.877B |
XLV Risk Info
| Beta (5Y) | 0.9106 |
| Max Drawdown (All) | 40.58% |
| Historical Sharpe (10Y) | 0.8143 |
| Historical Sortino (All) | 0.7062 |
| 30-Day Rolling Volatility | 8.28% |
| Daily Value at Risk (VaR) 1% (All) | 3.03% |
| Monthly Value at Risk (VaR) 1% (All) | 13.30% |
XLV Fundamentals
| Dividend Yield TTM (8-21-17) | 1.49% |
| SEC Yield (8-18-17) | 1.49% |
| Weighted Average PE Ratio | 23.55 |
| Weighted Average Price to Sales Ratio | 1.898 |
| Weighted Average Price to Book Ratio | 3.941 |
| Weighted Median ROE | 22.60% |
| Weighted Median ROA | 8.24% |
| Forecasted Dividend Yield | 1.69% |
| Forecasted PE Ratio | 21.20 |
| Forecasted Price to Sales Ratio | 1.771 |
| Forecasted Price to Book Ratio | 3.446 |
| Number of Holdings | 62 |
XLV Growth Estimates
| Forecasted 5 Yr Earnings Growth | 9.05% |
| Forecasted Book Value Growth | 9.14% |
| Forecasted Cash Flow Growth | 14.42% |
| Forecasted Earnings Growth | 11.75% |
| Forecasted Revenue Growth | 9.95% |
XLV Comparables
EditXLV Attributes
| Key Dates | |
|---|---|
| Inception Date | 12/16/1998 |
| Last Annual Report Date | 9/30/2016 |
| Last Prospectus Date | 1/31/2017 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
XLV Excel Add-In Codes
- Name: =YCI("XLV","name")
- Broad Asset Class: =YCI("XLV", "broad_asset_class")
- Broad Category: =YCI("XLV", "broad_category_group")
- Prospectus Objective: =YCI("XLV", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
